lirentelimab (AK002)

DRUG4 trials

Sponsors

Allakos Inc.

Conditions

Chronic Spontaneous UrticariaEosinophilic DuodenitisEosinophilic EsophagitisEosinophilic GastritisStudy Conducted in Healthy Volunteers

Phase 1

A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers

CompletedNCT04324268

Allakos Inc.Study Conducted in Healthy Volunteers

Start: 2020-03-23End: 2021-02-10Updated: 2023-04-18

Phase 2

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis

CompletedNCT04322708

Allakos Inc.Eosinophilic Esophagitis

Start: 2020-07-06End: 2022-01-18Updated: 2024-01-02

A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria

TerminatedNCT05528861

Allakos Inc.Chronic Spontaneous Urticaria

Start: 2022-10-26End: 2024-04-18Updated: 2024-09-27

Phase 3

A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

CompletedNCT04322604

Allakos Inc.Eosinophilic Duodenitis, Eosinophilic Gastritis

Start: 2020-06-18End: 2022-01-12Updated: 2024-01-02

Related Papers

Psychometric evaluation of the Dysphagia Symptom Questionnaire for adults and adolescents with eosinophilic esophagitis.

2024-07-162 citations

S446 Results from KRYPTOS, a Phase 2/3 Study of Lirentelimab (AK002) in Adults and Adolescents With EoE

The American Journal of Gastroenterology2022-10-0142 citations

S449 Lirentelimab (AK002) Safety and Efficacy in Patients With Higher Eosinophil Thresholds: Supplementary Analysis of Phase 2/3 EoE KRYPTOS Trial

The American Journal of Gastroenterology2022-10-012 citations